Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
2008 StandoutScience
Accelerated telomere shortening in response to life stress
2004 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
T cell defined tumor antigens
1997
In vivo cyclic induction of the FOXM1 transcription factor delays natural and progeroid aging phenotypes and extends healthspan
2022
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Chronic Myeloproliferative Disorders
2003
Induction of anti-self-immunity to cure cancer
1995
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
Tumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
1992
Bone marrow transplantation for sickle cell anemia: Progress and prospects
2004
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
The role of CD4+ T cell responses in antitumor immunity
1998
RAS oncogenes: weaving a tumorigenic web
2011
Immunology and immunotherapy approaches for prostate cancer
2007
Hallmarks of aging: An expanding universe
2023 Standout
CTLA-4: new insights into its biological function and use in tumor immunotherapy
2002 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Specificity in cancer immunotherapy
2008
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
1998 StandoutNature
Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
2012
Structure of peptides associated with MHC class I molecules
1994
Pancreatic Adenocarcinoma
2014 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Biology of Natural Killer Cells
1989 Standout
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Murine interleukin-4 displays potent anti-tumor activity in vivo
1989
Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging
1997
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.
1994 StandoutNobel
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
1994 StandoutNature
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
1998 StandoutNature
Immunotherapy for prostate cancer
2006
Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals
1998
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Switching and Signaling at the Telomere
2001 StandoutNobel
Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy
1996
Structure of 20S proteasome from yeast at 2.4Å resolution
1997 StandoutNatureNobel
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
1999 StandoutNobel
Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells
1991
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
1995 Standout
Immunotherapy for prostate cancer
2007
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
1997 StandoutNobel
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Isolating gene-corrected stem cells without drug selection
2005 StandoutNobel
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]
1995 Standout
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
1991 StandoutScience
Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo
1999
Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells
1998 StandoutNobel
CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
1998 StandoutNobel
Improving Prospects for Targeting RAS
2015
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Direct activation of TERT transcription by c-MYC
1999
Second-Line Treatment of Ovarian Cancer
2000
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
1990
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
1993 Standout
Immortalization of Human CD8+ T Cell Clones by Ectopic Expression of Telomerase Reverse Transcriptase
2000
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
1994
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
2001 StandoutNobel
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
The biology and treatment of acute lymphoblastic leukemia in adults
1995
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor
2000
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients
2008
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.
1987
Enhancement of Antitumor Immunity by CTLA-4 Blockade
1996 StandoutScienceNobel
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
1999
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Constitutive class I-restricted exogenous presentation of self antigens in vivo.
1996 StandoutNobel
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
1994 Science
Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.
1994
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999 StandoutNobel
Works of David Peace being referenced
Changes in Telomerase Activity and Telomere Length during Human T Lymphocyte Senescence
1997
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide
2005
The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells
2015
Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen
1997
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease
2000
T‐Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR‐ABLa
1993
High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.
1997
IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
1988
Potential Uses of Interleukin 2 in Cancer Therapy
1986
Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.
1988
Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
1986
T-cell immunity to the joining region of p210BCR-ABL protein.
1992
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
2002
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.
1989
Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
1994
Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
1987
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
1995
T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes
1991